.jpg?format=webp&width=780)
A new study has shown that icosapent ethyl (IPE) improves coronary physiology, as measured by fractional flow reserve derived from coronary computed tomography angiography (CTA) data sets (FFRCT), in patients with atherosclerosis or diabetes and elevated triglycerides. The study, which is the first to assess the impact of IPE on FFRCT, demonstrated significant improvement in the primary endpoint, as IPE improved mean distal segment FFRCT at 9- and 18-month follow-up compared with placebo. The early and sustained improvement in FFRCT provides mechanistic insight into the clinical benefit observed in the REDUCE-IT trial, which showed that IPE significantly reduced ischaemic events in statin-treated patients with elevated triglycerides.
Like
Save
Share